Unique Value Creation Model
Discover Our Model
Global
Partnerships
Value Realization
Clinical validation
Global out-licensing deals
New CD47 Antibodies
Commercial
Partnerships
Value Realization
Fast-to-market in China
Maximize commercial value
Eftansomatropin Alfa
Innovation
R&D Engine
Competitive advantages in immuno-oncology
Globally competitive pipeline in 3 generations
Our Proven Value Creation Model Is
Enabled by Differentiated Global Capabilities
Deep Immunology Expertise
- Led by principal scientists with decades of research and drug discovery expertise in pharma R&D
- Extensive research in immune regulatory pathways
- 200+ publications by in-house experts in high-impact scientific journals
- 12 novel drug molecules advanced into the clinic since 2016
Global Clinical Development
- Led by world-renowned oncologists with global clinical and drug development expertise in hematology and solid tumors
- Excellent track record in developing innovative oncology drugs
- 300+ medical science publications by in-house experts in high-impact journals
- 14 trials conducted in China, 8 trials conducted in the US, involving more than 1,000 patients worldwide by I-Mab
Note: Achievements accumulated during their careers.
Shanghai – Global HQ
- Global corporate operations
- Discovery powerhouse
- Clinical operations in multiple sites across China
Maryland – Global HQ
- Global clinical development
- Clinical operations in multiple sites across the U.S.
Other Locations
- Beijing – Clinical operations and regulatory
- Guangzhou – Clinical operations
- I-Mab Hangzhou – GMP manufacturing facility
- Lishui – GSP company
- Hong Kong – Capital market
- San Diego – Translational medicine
Global Partnerships
- > 15 deals
- ~ $1.5B total deal value
- Including the landmark deal with AbbVie
Commercial Partnerships
- > 5 deals
- ~ $345M total deal value
- Including the landmark deal with Jumpcan
Note: Refers to the aggregate value for the relevant deals that the Company entered into on a cumulative basis. For details of each relevant deal, please refer to the disclosure filed or furnished by the Company with the SEC.
Our business is powered by our diverse and experienced global talents
-
70%
R&D Personnel
-
70%
Female Employees
-
61%
Global Experience
-
60%
Advanced Degrees